Background The introduction of donors other than HLA-matched siblings has been a pivotal
change in stem cell transplantation. We aimed to assess the evolution of outcomes within …

Recognition of HLA incompatibilities by the immune system represents a major barrier to
allogeneic hematopoietic stem cell transplantation. HLA genotypically identical sibling …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a proven curative therapy for
many hematologic malignancies. HSCT from HLA-identical sibling donors (ISDs) is still the …

The use of HLA-mismatched donors could enable more patients with ethnically diverse
backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United …

Haploidentical hematopoietic stem cell transplants (HSCTs) are increasingly used, but it is
unknown whether they have a stronger graft-versus-leukemia (GVL) effect. We analyzed 10 …

Allogeneic hematopoietic stem cell transplantation (SCT) may cure patients with
hematologic malignancies, but it carries significant risks. Careful donor selection is an …

To validate current donor selection strategies based on previous international studies, we
retrospectively analyzed 2646 transplantations performed for hematologic malignancies in …

One of the major factors that have contributed to improving the outcomes of Stem Cell
Transplantation is progress made in the field of human leucocyte antigen (s)(HLA). This is …

The association between HLA matching and outcome in unrelated-donor peripheral blood
stem cell (PBSC) transplantation has not yet been established. In the present study, a total of …

Transplantation of hematopoietic stem cells is now well established as life‐saving therapy
for patients with several different genetic and acquired diseases. This has been possible …